Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | POLA1 | P09884 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19698977 | 1.00 | PDE4D (0.58) | PDE4DPDE3ASLC29A1POLA1POLB | |
| SCHEMBL13160956 | 1.00 | PDE4D (0.58) | PDE4DPDE3ASLC29A1POLA1POLB | |
| SCHEMBL18270576 | 1.00 | PDE4D (0.58) | PDE4DPDE3ASLC29A1POLA1POLB | |
| SCHEMBL13161076 | 0.92 | PDE4D (0.50) | PDE4DPDE3ASLC29A1POLA1POLB | |
| SCHEMBL31216570 | 0.92 | PDE4D (0.48) | PDE4DPDE3ASLC29A1POLA1POLB | |
| SCHEMBL19229320 | 0.91 | PDE4D (0.47) | PDE4DPDE3ASLC29A1POLBABL1 | |
| SCHEMBL13161023 | 0.90 | PDE4D (0.55) | PDE4DPDE3ASLC29A1POLA1POLB | |
| SCHEMBL17195657 | 0.89 | ADORA3 (0.44) | PDE4DPDE3ASLC29A1POLBABL1 | |
| SCHEMBL17109592 | 0.89 | PDE4D (0.45) | PDE4DPDE3ASLC29A1POLA1POLB | |
| SCHEMBL16252436 | 0.89 | PDE4D (0.45) | PDE4DPDE3ASLC29A1POLA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2020-11-19 | — | — | US | disclosed |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2020-11-19 | — | — | US | disclosed |
| US-9919060-B2 | Treatment or prophylaxis of proliferative conditions | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2018-03-20 | — | — | US | disclosed |
| US-9919060-B2 | Treatment or prophylaxis of proliferative conditions | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2018-03-20 | — | — | US | disclosed |
| US-20170368188-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2017-12-28 | — | — | US | disclosed |
| US-8283340-B2 | Treatment or prophylaxis of proliferative conditions | The University of the University of Dundee (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8283340-B2 | Treatment or prophylaxis of proliferative conditions | The University of the University of Dundee (GB) | 2012-10-09 | — | — | US | disclosed |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-07-26 | — | — | US | disclosed |
| EP-2424524-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
| WO-2010125350-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125350-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | BRCA1, CYP1B1, UGT1A1 | PDE4D 2580/4885PDE3A 2255/4885SLC29A1 939/4885 |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | PDE4D 2184/4885PDE3A 1792/4885SLC29A1 545/4885 |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | PDE4D 2184/4885PDE3A 1792/4885SLC29A1 545/4885 |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | PDE4D 2184/4885PDE3A 1792/4885SLC29A1 545/4885 |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, BRCA1, UGT1A1 | PDE4D 1981/4885PDE3A 1627/4885SLC29A1 634/4885 |
| US-20170368188-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | PDE4D 2607/4885PDE3A 1921/4885SLC29A1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.